Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Rev Esp Enferm Dig ; 2024 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-38685905

RESUMO

Following the growing trend of trying to individualise treatment in inflammatory bowel disease and in view of the challenge posed by elderly patients requiring biologic treatments, we have conducted a study in our centre to assess the T3/T4 index as a predictor of response to biologic treatments in elderly patients.

2.
Int J Med Sci ; 15(1): 10-15, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29333082

RESUMO

BACKGROUND: The production of anti-drug antibodies (ADAs) against IgG monoclonal antibodies (mAbs) targeting tumour necrosis factor (TNF) is an important cause of loss of response to anti-TNF mAbs in patients with inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC). Since receptors for the Fc portion of IgG (FCGRs) are involved in the degradation of IgG complexes, we hypothesised that a polymorphism in FCGR3A (V158F; rs396991) gene could be involved in anti-TNF ADA generation and treatment resistance. MATERIAL AND METHODS: A cohort of 103 IBD patients (80 CD, 23 UC) were genotyped and serum level of both anti-TNFs (infliximab or adalimumab) and ADA against them were measured. RESULTS: No significant differences were observed between ADA occurrence or V158F genotype and type of disease or the kind of anti-TNF administrated. Interestingly, VV genotype correlated with patients producing ADA (VV: 37.5% vs. FV: 10.6% or FF: 5%; p=0.004) and was an independent predictor of this event after multivariate analysis. Moreover, VV genotype also correlated with those patients receiving anti-TNF dose intensification (p=0.03). CONCLUSION: FCGR3A V158F polymorphism seems to be associated with ADA production against mAbs and it could be taken into account when considering the dose and type of anti-TNF in IBD patients.


Assuntos
Anticorpos Anti-Idiotípicos/imunologia , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Fármacos Gastrointestinais/imunologia , Receptores de IgG/genética , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab/sangue , Adalimumab/imunologia , Adalimumab/uso terapêutico , Adulto , Anticorpos Anti-Idiotípicos/sangue , Estudos de Coortes , Colite Ulcerativa/sangue , Colite Ulcerativa/genética , Colite Ulcerativa/imunologia , Doença de Crohn/sangue , Doença de Crohn/genética , Doença de Crohn/imunologia , Feminino , Fármacos Gastrointestinais/uso terapêutico , Humanos , Infliximab/sangue , Infliximab/imunologia , Infliximab/uso terapêutico , Masculino , Pessoa de Meia-Idade , Polimorfismo Genético , Receptores de IgG/imunologia
3.
Rev Esp Enferm Dig ; 108(10): 670-672, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26887434

RESUMO

Gastric involvement with the varicella-zoster virus is an uncommon clinical condition where early suspicion and diagnosis are important to prevent the consequences deriving from its high morbidity and mortality, which in immunocompromised patients oscillate between 9% and 41% according to the various series. Two cases of gastric involvement with the varicella-zoster virus (VZV) in two patients with blood cancer are reported below. Gastric lesions are usually preceded by typical papulovesicular skin lesions. When gastric involvement is the first symptom of the disease its diagnosis and management may be delayed, which may entail severe consequences for immunocompromised patients. It is therefore that we suggest its inclusion in the algorithm for immunocompromised patients with abdominal pain and ulcer-like endoscopic lesions.


Assuntos
Varicela/complicações , Varicela/tratamento farmacológico , Neoplasias Hematológicas/complicações , Gastropatias/complicações , Gastropatias/tratamento farmacológico , Dor Abdominal , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Feminino , Humanos , Hospedeiro Imunocomprometido , Pessoa de Meia-Idade
4.
Eur J Clin Pharmacol ; 69(3): 431-8, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22960943

RESUMO

AIM: Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are partially attributable to an increased secretion of proinflamatory cytokines, such as tumour necrosis factor (TNF) and interleukin-1ß (IL1ß), which play essential roles in the disease pathogenesis and are target molecules for specific therapy. Given the inter-individual variability in the response to the anti-TNF monoclonal antibody infliximab, the aim of our study was to explore the predictive value of TNF and/or IL1ß as surrogate markers of infliximab response. METHODS: Serial serum concentrations of TNF and IL1ß and TNF promoter region and IL1B polymorphisms were determined in 47 patients (29 CD and 18 UC) receiving infliximab and correlated with treatment response. RESULTS: Baseline serum concentrations of TNF and IL1ß were higher in UC patients than in CD patients (p = 0.0097 and 0.0024, respectively). CD patients showing <0.64 pg/ml IL1ß at baseline were more frequently responders than non-responders (p = 0.036), and the C allele of the IL1B polymorphism was associated with higher IL1ß serum concentrations (p = 0.026) and with poorer clinical remission after 14 weeks of infliximab treatment. No significant association was found between serum TNF concentration or TNF polymorphism and patient response to infliximab. CONCLUSION: This is the first study evaluating the pharmacogenetic role of the rs1143634 polymorphism of IL1B and TNF polymorphisms in infliximab-treated IBD patients. We found an association between the rs1143634 C allele and higher serum IL1ß concentrations and a lower response to infliximab treatment in CD patients that warrants the interest of future studies in larger and independent series.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Colite Ulcerativa/tratamento farmacológico , Doença de Crohn/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Mediadores da Inflamação/sangue , Interleucina-1beta/sangue , Interleucina-1beta/genética , Polimorfismo Genético , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/genética , Adolescente , Adulto , Biomarcadores/sangue , Colite Ulcerativa/sangue , Colite Ulcerativa/genética , Colite Ulcerativa/imunologia , Doença de Crohn/sangue , Doença de Crohn/genética , Doença de Crohn/imunologia , Feminino , Frequência do Gene , Genótipo , Humanos , Infliximab , Masculino , Fenótipo , Regiões Promotoras Genéticas , Indução de Remissão , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
5.
Gastroenterol Hepatol ; 30(8): 457-60, 2007 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-17949612

RESUMO

Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV infection, the frequency of tuberculosis has recently shown a marked increase. Although the most frequent location of tuberculosis infection continues to be respiratory, infection in other sites, such as musculoskeletal, genitourinary, neurological and abdominal areas, has recently become more common. Abdominal infection, the most frequently described extrapulmonary localization, commonly affects the spleen, liver, ileocecal region, peritoneum, and regional lymph nodes. Tuberculosis of the pancreas is considered a rare entity.


Assuntos
Duodenopatias/etiologia , Fístula Intestinal/etiologia , Pancreatopatias/complicações , Tuberculose Gastrointestinal/complicações , Adulto , Infecções por HIV/complicações , Humanos , Masculino , Pancreatopatias/diagnóstico , Tuberculose Gastrointestinal/diagnóstico
7.
Rev. esp. enferm. dig ; 108(10): 670-672, oct. 2016. ilus
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-156754

RESUMO

La afectación gástrica por el virus varicela-zóster es una entidad clínica poco frecuente, cuya sospecha y diagnóstico precoz es importante para evitar las consecuencias derivadas de su elevada morbimortalidad que en pacientes inmunocomprometidos varía entre un 9% y 41% según las series. A continuación se describen dos casos de afectación gástrica por el virus de la varicela-zóster (VVZ) en dos pacientes con enfermedad hematooncológica. Habitualmente las lesiones gástricas van precedidas de la aparición de lesiones cutáneas pápulo-vesiculares características. Cuando la afectación gástrica es el primer síntoma de la enfermedad se puede producir un retraso en el diagnóstico y tratamiento de esta infección que puede conllevar consecuencias graves para el paciente inmunocomprometido. Es por ello que proponemos que sea una entidad tenida en cuenta en el algoritmo de estudio del paciente inmunocomprometido que presenta dolor abdominal y lesiones endoscópicas de tipo ulceroso (AU)


Gastric involvement with the varicella-zoster virus is an uncommon clinical condition where early suspicion and diagnosis are important to prevent the consequences deriving from its high morbidity and mortality, which in immunocompromised patients oscillate between 9% and 41% according to the various series. Two cases of gastric involvement with the varicella-zoster virus (VZV) in two patients with blood cancer are reported below. Gastric lesions are usually preceded by typical papulovesicular skin lesions. When gastric involvement is the first symptom of the disease its diagnosis and management may be delayed, which may entail severe consequences for immunocompromised patients. It is therefore that we suggest its inclusion in the algorithm for immunocompromised patients with abdominal pain and ulcer-like endoscopic lesions (AU)


Assuntos
Humanos , Varicela/complicações , Herpesvirus Humano 3/patogenicidade , Gastrite/virologia , Hospedeiro Imunocomprometido , Úlcera Gástrica/virologia , Dor Abdominal/etiologia , Leucemia/complicações , Linfoma não Hodgkin/complicações
8.
Gastroenterol. hepatol. (Ed. impr.) ; 30(8): 457-460, oct. 2007. ilus
Artigo em Es | IBECS (Espanha) | ID: ibc-62449

RESUMO

La tuberculosis es una entidad frecuente en todo el mundo. En los países desarrollados se describía hasta hace unos años un descenso en su incidencia, pero debido al aumento de flujos migratorios y a la aparición del sida, se ha detectado un notable aumento en su frecuencia en los últimos tiempos. A pesar de que la localización clásica con afectación pulmonar continúa siendo la forma de presentación más comunicada, se ha descrito un incremento en el diagnóstico en otras localizaciones. La afectación de otros órganos y aparatos, como el sistema muscular esquelético, el genitourinario, el neurológico o el abdominal, ha dejado de ser infrecuente. La abdominal es una localización extrapulmonar cada vez más frecuente, zona en la que se ha descrito una afectación de diversas estructuras: cadenas linfáticas mesentéricas, intestino delgado, peritoneo, hígado y bazo. La afectación pancreática es una entidad muy infrecuente


Tuberculosis is a common infection worldwide. In developed countries, the incidence of this disease was low until a few years ago. However, due to the rise in immigration and HIV infection, the frequency of tuberculosis has recently shown a marked increase. Although the most frequent location of tuberculosis infection continues to be respiratory, infection in other sites, such as musculoskeletal, genitourinary, neurological and abdominal areas, has recently become more common. Abdominal infection, the most frequently described extrapulmonary localization, commonly affects the spleen, liver, ileocecal region, peritoneum, and regional lymph nodes. Tuberculosis of the pancreas is considered a rare entity (AU)


Assuntos
Humanos , Masculino , Adulto , Tuberculose/diagnóstico , Fístula Intestinal/diagnóstico , Pancreatopatias/diagnóstico , Mycobacterium tuberculosis/isolamento & purificação , Mycobacterium tuberculosis/patogenicidade , Infecções por HIV/complicações , Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Biomarcadores/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA